课题基金 / 基金详情

Development plan of the new treatment for malignant glioma using Monocyte Chemoattrctant Protein-1

Development plan of the new treatment for malignant glioma using Monocyte Chemoattrctant Protein-1
单核细胞趋化蛋白-1治疗恶性胶质瘤新疗法的开发计划
批准号:
09671430
负责人:
KURATSU Jun-ichi
金额:
$1.92万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998

项目摘要

项目成果

KURATSU Jun-ichi的其他基金

相似基金

相关文献

中文摘要
翻译
我们先前从人脑胶质瘤细胞系培养上清液中纯化了人单核细胞趋化蛋白-1(MCP-1)。单核细胞趋化蛋白-1是C-C趋化因子中的一员,主要作用于单核细胞的趋化。克隆MCP-1基因后,我们对该基因在多种脑肿瘤中的表达进行了分析。发现肿瘤组织中MCP-1的表达与肿瘤相关巨噬细胞数量呈正相关。MCP-1受体,命名为hCCR2,是人类免疫缺陷病毒(HIV)进入细胞所必需的辅助受体,也是MCP-1的受体。为了阐明hCCR2转录调控的分子机制,我们对hCCR2基因进行了克隆和测序。在5-侧翼区域,存在典型的哺乳动物启动子共同元件,即CAAT盒和TATA盒,导致了单一的转录起始点。此外,我们还发现,渗透到胶质瘤组织中的显微图像表达了在新生血管中起重要作用的酪氨酸磷酸化酶。我们认为单核细胞趋化蛋白-1活性的调节和巨噬细胞CCR2表达的调控可能导致胶质瘤的生长控制。
英文摘要
We previously purified the human monocyte chemoattractant protein-1(MCP-1) from supernatant of cultured human glioma cell lines. MCP-1 is a member of the C-C chemokines that medicate monocyte chemotaxis. After cloning of the MCP-1 cDNA, ewe hacve analyzed the expression of the gene In a variety of brain tumors. We found the therewas a positive correatlon between the amount of MCP-1 expression of the tumors and the number of tumor associated macrophages. Furthermore, a transfection experiment demonstrated that excessive expression of this chemokine could induce macrophage infiltration and suppression In vivo tumor growth.The MCP-1 receptor, designated hCCR2, is an essential co-receptor In cell entry by the human immunodeficiency virus (HIV) as , well as a receptor for MCP-1. To elucidate the molecular mechanisms for transcriptional regulation of hCCR2, we cloned and sequenced the hCCR2 gene. In the 5-flanking region, there were the typical mammalian promotor consensus elements, a CAAT box and a TATA box resulting in a single transcription-Initiation site.Furthermore, we found that macraphages infiltrated into the glioma tissue express the tyrosine phosphorylase which play an important role on the neovascularization. We posit the regulation of MCP-1 activity and the control of the CCR2 expression of macrophages should lead to the growth control of glioma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nishi T.: "Treatment of cancer using pulsed eletctric-field in combination with chemotherapeutic agents or genes" Human Cell. 10(1). 81-86 (1997)
Nishi T.:“使用脉冲电场结合化疗药物或基因治疗癌症”《人类细胞》。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yamamoto Ket al.: "Cloning and functional characterization of the 5'-flanking region of the human monocyte chemoattractant protain-1 receptor(CCR2)gene.-Essential role of 5' untranslated region in tissue specific expression." J. Biol. Chem.274(in press).
Yamamoto Ket al.:“人单核细胞趋化蛋白 protain-1 受体 (CCR2) 基因 5 侧翼区域的克隆和功能表征。-5 非翻译区域在组织特异性表达中的重要作用。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Development of new anti-tumor therapy for malignant glioma using a drug incorporating polymeric micelle attached with a specific antibody for glioma cancer stem cell
  • 批准号:
    23390351
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 资助金额:
    $12.15万
  • 财政年份:
    2011
  • 负责人:
    KURATSU Jun-ichi
  • 依托单位:
Deep brain stimulation and neuronal reorganization
  • 批准号:
    20591714
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.83万
  • 财政年份:
    2008
  • 负责人:
    KURATSU Jun-ichi
  • 依托单位:
The pathophysiology of malignant glioma and treatment strategies
  • 批准号:
    17390404
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 资助金额:
    $10.59万
  • 财政年份:
    2005
  • 负责人:
    KURATSU Jun-ichi
  • 依托单位:
The pathophysiology of malignant glioma and of treatment strategies
国内基金
海外基金
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
  • 批准号:
    81271563
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2012
  • 负责人:
    陈正光
  • 依托单位: